rabeprazole has been researched along with Adenoma in 5 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Adenoma: A benign epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs)." | 9.22 | Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. ( Hasui, T; Inaba, T; Ishida, M; Ishikawa, S; Iwamuro, M; Izumikawa, K; Kagawa, T; Kuraoka, S; Matsuura, M; Sakakihara, I; Sasaki, K; Takahashi, S; Tanaka, S; Wato, M; Yamamoto, K, 2016) |
| "In this prospective, randomized, multicenter, open-label, and comparative study, patients who had undergone ESD for EGC or gastric adenoma were randomized into groups receiving either rabeprazole monotherapy (10 mg/day, n=64) or a combination of rabeprazole plus rebamipide (300 mg/day, n=66)." | 5.22 | Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy. ( Akahoshi, K; Akiho, H; Aso, A; Harada, N; Iboshi, Y; Ihara, E; Iwasa, T; Nakamura, K; Nakamura, N; Ochiai, T; Ogino, H; Takayanagi, R, 2016) |
| "Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs)." | 5.22 | Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. ( Hasui, T; Inaba, T; Ishida, M; Ishikawa, S; Iwamuro, M; Izumikawa, K; Kagawa, T; Kuraoka, S; Matsuura, M; Sakakihara, I; Sasaki, K; Takahashi, S; Tanaka, S; Wato, M; Yamamoto, K, 2016) |
| "Patients with early gastric cancers that are limited to gastric mucosa or submucosa usually have an advanced loss of mucosal glandular tissue (glandular atrophy) and are at high risk for subsequent (metachronous) development of new gastric cancer." | 2.87 | Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. ( Cho, SJ; Choi, IJ; Kim, CG; Kim, YI; Kook, MC; Lee, JY; Nam, BH; Park, B, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, IJ | 1 |
| Kook, MC | 1 |
| Kim, YI | 1 |
| Cho, SJ | 1 |
| Lee, JY | 1 |
| Kim, CG | 1 |
| Park, B | 1 |
| Nam, BH | 1 |
| Hikichi, T | 1 |
| Sato, M | 1 |
| Watanabe, K | 1 |
| Nakamura, J | 1 |
| Takagi, T | 1 |
| Suzuki, R | 1 |
| Sugimoto, M | 1 |
| Waragai, Y | 1 |
| Kikuchi, H | 1 |
| Konno, N | 1 |
| Ohira, H | 1 |
| Obara, K | 1 |
| Nakamura, K | 1 |
| Ihara, E | 1 |
| Akiho, H | 1 |
| Akahoshi, K | 1 |
| Harada, N | 1 |
| Ochiai, T | 1 |
| Nakamura, N | 1 |
| Ogino, H | 1 |
| Iwasa, T | 1 |
| Aso, A | 1 |
| Iboshi, Y | 1 |
| Takayanagi, R | 1 |
| Kagawa, T | 1 |
| Iwamuro, M | 1 |
| Ishikawa, S | 1 |
| Ishida, M | 1 |
| Kuraoka, S | 1 |
| Sasaki, K | 1 |
| Sakakihara, I | 1 |
| Izumikawa, K | 1 |
| Yamamoto, K | 1 |
| Takahashi, S | 1 |
| Tanaka, S | 1 |
| Matsuura, M | 1 |
| Hasui, T | 1 |
| Wato, M | 1 |
| Inaba, T | 1 |
| Sato, H | 1 |
| Abe, K | 1 |
| Oshima, N | 1 |
| Kawashima, K | 1 |
| Hamamoto, N | 1 |
| Moritani, M | 1 |
| Mak, R | 1 |
| Ishihara, S | 1 |
| Adachi, K | 1 |
| Kawauchi, H | 1 |
| Kinoshita, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Helicobacter Pylori Eradication on Glandular Atrophy and Metachronous Cancer in Patients Undergoing Endoscopic Mucosal Resection for Gastric Cancer[NCT02407119] | Phase 3 | 470 participants (Actual) | Interventional | 2003-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for rabeprazole and Adenoma
| Article | Year |
|---|---|
Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer.
Topics: Adenoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug | 2018 |
Oral rabeprazole administration on a procedure day suppresses bleeding after endoscopic submucosal dissection for gastric neoplasms.
Topics: Adenocarcinoma; Adenoma; Administration, Oral; Aged; Aged, 80 and over; Female; Gastrointestinal Hem | 2014 |
Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy.
Topics: Adenoma; Aged; Alanine; Anti-Ulcer Agents; Drug Therapy, Combination; Endoscopic Mucosal Resection; | 2016 |
Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.
Topics: Adenoma; Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Gastrointestinal Hemorrhage; | 2016 |
1 other study available for rabeprazole and Adenoma
| Article | Year |
|---|---|
Primary hyperparathyroidism with duodenal ulcer and H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Aged; Anti-Ulcer Agents; Benzimidazoles; Duodenal | 2002 |